Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth

Molecular Pharmacology

Volumn 81, Issue 6, 2012, Pages 811-819

  Tan, Zongqing ^a   Wortman, Matthew ^a   Dillehay, Kelsey L ^a   Seibel, William L ^a   Evelyn, Chris R ^b   Smith, Shanna J ^c   Malkas, Linda H ^c   Zheng, Yi ^b   Lu, Shan ^a   Dong, Zhongyun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANTIGEN STRUCTURE; ANTIGENIC MODULATION; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CHROMATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 84861428331     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.077735     Document Type: Article

References (48)

1. Alhamadsheh MM, Connelly S, Cho A, Reixach N, Powers ET, Pan DW, Wilson IA, Kelly JW, and Graef IA (2011) Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med 3:97ra81.
2. Almendral JM, Huebsch D, Blundell PA, Macdonald-Bravo H, and Bravo R (1987) Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci USA 84:1575-1579. (Pubitemid 17066730)
3. Baliga R, Zhang Z, Baliga M, Ueda N, and Shah SV (1998) In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53:394-401. (Pubitemid 28097855)
4. Bowman GD, O'Donnell M, and Kuriyan J (2004) Structural analysis of a eukaryotic sliding DNA clamp-clamp loader complex. Nature 429:724-730. (Pubitemid 38833117)
5. Bravo R and Celis JE (1980) A search for differential polypeptide synthesis throughout the cell cycle of HeLa cells. J Cell Biol 84:795-802. (Pubitemid 10122239)
6. Bravo R and Macdonald-Bravo H (1987) Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol 105:1549-1554. (Pubitemid 18023377)
7. Cappello F, Ribbene A, Campanella C, Czarnecka AM, Anzalone R, Bucchieri F, Palma A, and Zummo G (2006) The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review. Eur J Histochem 50:25-34. (Pubitemid 351480080)
8. Celis JE and Olsen E (1994) A qualitative and quantitative protein database approach identifies individual and groups of functionally related proteins that are differentially regulated in simian virus 40 (SV40) transformed human keratinocytes: an overview of the functional changes associated with the transformed phenotype. Electrophoresis 15:309-344. (Pubitemid 24151835)
9. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12-21.
10. Dong ZY, Ward NE, Fan D, Gupta KP, and O'Brian CA (1991) In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39:563-569.
11. Eltz S, Comperat E, Cussenot O, and Rouprêt M (2008) Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int 102:532-535.
12. Gulbis JM, Kelman Z, Hurwitz J, O'Donnell M, and Kuriyan J (1996) Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell 87:297-306. (Pubitemid 26359007)
13. Hasinoff BB and Patel D (2009) The iron chelator Dp44mT does not protect myocytes against doxorubicin. J Inorg Biochem 103:1093-1101.
14. 1/S progression during hyperoxia. Am J Physiol Lung Cell Mol Physiol 286:L506-L513.
15. Jerabek-Willemsen M, Wienken CJ, Braun D, Baaske P, and Duhr S (2011) Molecular interaction studies using microscale thermophoresis. Assay Drug Dev Technol 9:342-353.
16. Jiao Y, Wilkinson J 4th, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R Jr, Knovich MA, Torti FM, and Torti SV (2009) Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113:462-469.
17. Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr, Rifkin MD, and Ross JS (1999) The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 85:1569-1576. (Pubitemid 29152830)
18. 2/M transition. Oncogene 21:1717-1726.
19. Kelman Z and O'Donnell M (1995) Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Nucleic Acids Res 23:3613-3620.
20. Killion JJ, Radinsky R, Dong Z, Fishbeck R, Whitworth P, and Fidler IJ (1993) The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype. Cancer Immunol Immunother 36:381-386. (Pubitemid 23146825)
21. Kim BJ and Lee H (2008) Lys-110 is essential for targeting PCNA to replication and repair foci, and the K110A mutant activates apoptosis. Biol Cell 100:675-686.
22. Kimos MC, Wang S, Borkowski A, Yang GY, Yang CS, Perry K, Olaru A, Deacu E, Sterian A, Cottrell J, et al. (2004) Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression. Int J Cancer 111:415-417. (Pubitemid 38998823)
23. Kontopidis G, Wu SY, Zheleva DI, Taylor P, McInnes C, Lane DP, Fischer PM, and Walkinshaw MD (2005) Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci USA 102:1871-1876. (Pubitemid 40261979)
24. Luo Y, Hurwitz J, and Massagué J (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375:159-161.
25. Maga G and Hubscher U (2003) Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116:3051-3060. (Pubitemid 37038954)
26. Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, et al. (2006) A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci USA 103:19472-19477. (Pubitemid 46026055)
27. Merlot AM, Pantarat N, Lovejoy DB, Kalinowski DS, and Richardson DR (2010) Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. Mol Pharmacol 78:675-684.
28. Miyamoto S, Ito K, Kurokawa K, Suzuki K, Suzuki K, and Yamanaka H (2006) Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer. Int J Urol 13:767-772. (Pubitemid 43926770)
29. Moldovan GL, Pfander B, and Jentsch S (2007) PCNA, the maestro of the replication fork. Cell 129:665-679. (Pubitemid 46802385)
30. Mulligan JM, Mai KT, Parks W, and Gerridzen RG (1997) Proliferating cell nuclear antigen (PCNA) and MIB 1: Markers of locally advanced and biologically aggressive prostate cancer. Can J Urol 4:422-425.
31. Nakayama GR, Caton MC, Nova MP, and Parandoosh Z (1997) Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 204:205-208. (Pubitemid 27262014)
32. Naryzhny SN (2008) Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 65:3789-3808.
33. Naryzhny SN and Lee H (2007) Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal and cancer cells: there is no cancer-associated form of PCNA. FEBS Lett 581:4917-4920. (Pubitemid 47531762)
34. Naryzhny SN, Zhao H, and Lee H (2005) Proliferating cell nuclear antigen (PCNA) may function as a double homotrimer complex in the mammalian cell. J Biol Chem 280:13888-13894.
35. Park MJ, Park JH, Hahm SH, Ko SI, Lee YR, Chung JH, Sohn SY, Cho Y, Kang LW, and Han YS (2009) Repair activities of human 8-oxoguanine DNA glycosylase are stimulated by the interaction with human checkpoint sensor Rad9-Rad1-Hus1 complex. DNA repair 8:1190-1200.
36. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, and Shacter EB (2009) The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res 69:948-957.
37. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038. (Pubitemid 27172591)
38. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, and Takahashi T (1994) Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen. Br J Cancer 70:1060-1066. (Pubitemid 24358939)
39. Savio M, Stivala LA, Scovassi AI, Bianchi L, and Prosperi E (1996) p21waf1/cip1 protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites. Oncogene 13:1591-1598. (Pubitemid 26377489)
40. Song W, Levin DS, Varkey J, Post S, Bermudez VP, Hurwitz J, and Tomkinson AE (2007) A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. J Biol Chem 282:22721-22730. (Pubitemid 47267306)
41. Song W, Pascal JM, Ellenberger T, and Tomkinson AE (2009) The DNA binding domain of human DNA ligase I interacts with both nicked DNA and the DNA sliding clamps, PCNA and hRad9-hRad1-hHus1. DNA Repair (Amst) 8:912-919.
42. Stoimenov I and Helleday T (2009) PCNA on the crossroad of cancer. Biochemical Society transactions 37:605-613.
43. Stuart-Harris R, Caldas C, Pinder SE, and Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17:323-334.
44. Waga S and Stillman B (1998) The DNA replication fork in eukaryotic cells. Ann Rev Biochem 67:721-751. (Pubitemid 28411143)
45. Xu M, Bai L, Gong Y, Xie W, Hang H, and Jiang T (2009) Structure and functional implications of the human rad9-hus1-rad1 cell cycle checkpoint complex. J Biol Chem 284:20457-20461.
46. Yang L, Ye SD, Feng LG, Wang JS, and Zhai W (2002) [In vitro experiment of inhibiting cell proliferation on human esophageal squamous cell cancer T]. Tn cell line by proliferating cell nuclear antigen antisense oligodeoxynucleotide. Ai Zheng 21:276-280.
47. Zhang F, Lu W, and Dong Z (2002) Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res 8:2942-2951. (Pubitemid 35025743)
48. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, and Dai Q (2008) Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 31:E8-E15. (Pubitemid 351272175)